Free Trial

Cerevel Therapeutics (CERE) Competitors

+0.60 (+1.40%)
(As of 12:27 PM ET)


Should you be buying Cerevel Therapeutics stock or one of its competitors? The main competitors of Cerevel Therapeutics include CNX Resources (CNX), Warrior Met Coal (HCC), Arch Resources (ARCH), Hallador Energy (HNRG), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), and BeiGene (BGNE).

Cerevel Therapeutics vs.

CNX Resources (NYSE:CNX) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap oils/energy companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.

CNX Resources received 661 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. Likewise, 70.53% of users gave CNX Resources an outperform vote while only 66.52% of users gave Cerevel Therapeutics an outperform vote.

CNX ResourcesOutperform Votes
Underperform Votes
Cerevel TherapeuticsOutperform Votes
Underperform Votes

CNX Resources has higher revenue and earnings than Cerevel Therapeutics. Cerevel Therapeutics is trading at a lower price-to-earnings ratio than CNX Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CNX Resources$3.47B1.14$1.72B$5.524.68
Cerevel TherapeuticsN/AN/A-$432.84M-$2.73-15.71

CNX Resources presently has a consensus price target of $25.43, indicating a potential downside of 1.48%. Cerevel Therapeutics has a consensus price target of $42.67, indicating a potential downside of 0.54%. Given CNX Resources' stronger consensus rating and higher possible upside, analysts plainly believe Cerevel Therapeutics is more favorable than CNX Resources.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CNX Resources
1 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
Cerevel Therapeutics
0 Sell rating(s)
8 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)

In the previous week, CNX Resources had 5 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 8 mentions for CNX Resources and 3 mentions for Cerevel Therapeutics. CNX Resources' average media sentiment score of 0.75 beat Cerevel Therapeutics' score of 0.42 indicating that Cerevel Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CNX Resources
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Cerevel Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)

95.2% of CNX Resources shares are held by institutional investors. Comparatively, 87.7% of Cerevel Therapeutics shares are held by institutional investors. 3.1% of CNX Resources shares are held by company insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CNX Resources has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

CNX Resources has a net margin of 40.44% compared to CNX Resources' net margin of 0.00%. Cerevel Therapeutics' return on equity of 7.68% beat CNX Resources' return on equity.

Company Net Margins Return on Equity Return on Assets
CNX Resources40.44% 7.68% 3.72%
Cerevel Therapeutics N/A -98.94%-45.07%


CNX Resources beats Cerevel Therapeutics on 11 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CERE vs. The Competition

MetricCerevel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$7.82B$6.83B$4.95B$8.35B
Dividend YieldN/A2.85%5.25%3.96%
P/E Ratio-15.719.92104.4414.84
Price / SalesN/A292.752,159.8476.69
Price / CashN/A32.1033.7233.62
Price / Book11.565.834.854.63
Net Income-$432.84M$141.99M$105.58M$213.97M
7 Day Performance2.39%1.87%118.10%2.69%
1 Month Performance3.00%9.78%129.69%8.59%
1 Year Performance45.47%-2.71%132.10%3.64%

Cerevel Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNX Resources
3.1806 of 5 stars
3.18 / 5 stars
+39.8%$4.04B$1.37B4.69470Upcoming Earnings
Analyst Forecast
Warrior Met Coal
2.972 of 5 stars
2.97 / 5 stars
+68.2%$3.70B$1.68B8.52850Positive News
Arch Resources
3.7564 of 5 stars
3.76 / 5 stars
+27.6%$2.87B$3.15B9.313,400Upcoming Earnings
Hallador Energy
1.329 of 5 stars
1.33 / 5 stars
-3.9%$322.53M$634.48M14.76936Positive News
Alnylam Pharmaceuticals
3.9345 of 5 stars
3.93 / 5 stars
+18.9%$30.36B$1.83B-89.562,100Analyst Revision
Positive News
Teva Pharmaceutical Industries
3.5095 of 5 stars
3.51 / 5 stars
+97.5%$18.55B$15.85B-39.9537,851Positive News
Genmab A/S
4.023 of 5 stars
4.02 / 5 stars
-33.3%$17.74B$2.39B22.362,204Analyst Revision
Royalty Pharma
4.8094 of 5 stars
4.81 / 5 stars
-9.8%$16.79B$2.36B20.9751Dividend Announcement
News Coverage
BioMarin Pharmaceutical
4.7436 of 5 stars
4.74 / 5 stars
-4.1%$16.08B$2.42B79.123,401Upcoming Earnings
2.5548 of 5 stars
2.55 / 5 stars
-21.7%$14.90B$2.46B-20.3010,600Positive News

Related Companies and Tools

This page (NASDAQ:CERE) was last updated on 7/22/2024 by Staff

From Our Partners